Haoxi Health Technology Announces $6.5 Million Registered Direct Offering

Key Facts

Haoxi Health Technology (HAO) has announced a definitive agreement for a registered direct offering valued at approximately $6.5 million. The deal includes the sale of 9 million Class A ordinary shares and nearly 17 million pre-funded warrants. According to reports, the offering is directed toward institutional or private investors at a fixed purchase price of $0.25 per share.

This capital raise comes as US-listed Chinese health-tech firms face increasing financing pressures, where direct offerings at fixed prices often lead to equity dilution and short-term downward pressure on share prices. Compared to industry peers, this move reflects the company's necessity to secure immediate liquidity for operations, occurring alongside broader market volatility that saw mixed Services PMI data across global markets per market data.

Traders should monitor liquidity levels following the closing of the deal and the dilutive impact on HAO stock, which faces technical hurdles at penny-stock levels. Looking ahead, investors are eyeing the US Initial Jobless Claims data scheduled for May 7, 2026, as a potential catalyst for general risk appetite in small-cap equities.